Cellebrite DI Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Cellebrite DI (CLBT)

Cellebrite DI reported third-quarter results above key estimates on November 12, 2026, yet its shares traded down about 14% after the same report trimmed full-year revenue guidance again. Investors who lost money in the reversal may have legal rights.

NEW YORK, Nov. 13, 2026 /PRNewswire/ -- Cellebrite DI (NASDAQ: CLBT) topped FactSet's third-quarter revenue estimate by $3.2 million on November 12, 2026, and by that afternoon its stock was down about 14%. If you bought CLBT shares and are holding a loss from that selloff, now is the time to act. Shareholders who lost money in the November 12 reversal are encouraged to submit their loss details now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

The day started with the headline numbers. Cellebrite reported quarterly revenue of $149.0 million against a FactSet estimate of $145.8 million, and earnings of $0.17 per share against a pre-release estimate of $0.09. CLBT traded higher before the open and gapped up after the release.

The gain did not hold. The same report trimmed full-year revenue guidance again, following an earlier guidance cut in August. It also set fourth-quarter revenue guidance at $145 million to $150 million and left full-year ARR guidance unchanged. By afternoon trading, CLBT shares had reversed to a loss of about 14%. Levi & Korsinsky is investigating potential securities law violations on behalf of investors who suffered losses.

If the November 12 reversal cost you money on Cellebrite shares, request a free review of your CLBT losses or call (212) 363-7500.

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the CLBT Investigation

Q: How much did CLBT stock drop?A: Shares fell approximately 14% on November 12, 2026, after Cellebrite DI released third-quarter results that included another reduction to its full-year revenue guidance. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Cellebrite DI made materially false or misleading statements regarding its revenue outlook and full-year guidance. When the Company disclosed another trim to its full-year revenue guidance on November 12, 2026, the stock price declined sharply.

Q: When did Cellebrite DI allegedly mislead investors?A: The investigation concerns statements made before the November 12, 2026 disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do CLBT investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my CLBT shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CLBT and sold at a loss may still participate in the investigation.

Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP